Finch Therapeutics

Finch Therapeutics is a microbiome technology company focused on developing innovative therapies based on the gut microbiome. They hold a robust intellectual property estate, boasting over 70 issued U.S. and foreign patents, which reflects their pioneering role in the microbiome therapeutics field. Their portfolio includes CP101, an orally administered microbiome candidate with positive clinical data in recurrent C. difficile infection (CDI), as well as pre-clinical assets targeting conditions like ulcerative colitis, Crohn’s disease, and autism spectrum disorder.

While Finch previously focused on developing CP101 as a treatment for recurrent CDI, they have recently shifted their strategy. The company discontinued its Phase 3 trial of CP101 in January 2023 and is now concentrating on realizing the value of its intellectual property estate and other assets. They are actively seeking partnerships and collaborations to advance their microbiome technology and bring novel therapies to patients in need.

Finch Therapeutics is a microbiome technology company dedicated to developing innovative therapies that harness the power of the human microbiome to transform lives. Their mission is to advance the understanding and application of the microbiome, with a focus on creating novel treatments for conditions like recurrent C. difficile infection, ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Their commitment to scientific innovation and patient well-being drives their efforts to realize the potential of the microbiome as a new therapeutic modality.

Finch Therapeutics promotes a culture of innovation and collaboration, driven by a passion for developing microbiome therapeutics that transform lives. Their commitment to pioneering work in the field is evident in their robust intellectual property estate and their partnerships with leading researchers and institutions. The company values a diverse and inclusive environment where employees are encouraged to contribute their unique perspectives and expertise.